tbuckley/cabot-search huggingface dataset:
Abstract B42: Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment
Authors: Didier Ritter, David Piquemal, Florian Noguier, Fabien Pierrat, Roman Bruno
Journal: Cancer Research (2019)

Abstract Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. If no action is taken, it is set to be 2nd by 2021. For nearly 80% of patients, diagnosis occurs at an advanced stage, too late (metastatic pancreatic adenocarcinoma; mPDAC), making them nonelective for surgery. The high mortality rate (less than 5% of patients alive at 5 years), is partly due to the difficulty to diagnose and to the lack of patients’ stratification for effective treatments. Despite advances in treatment and outcomes, the capability of biomarkers to improve treatment is potentially greater than in any other area of current medical research. Based on a multicenter, randomized, retrospective clinical phase III evaluation (ClinicalTrials.gov: NCT00789633), Acobiom identified an 11-gene blood signature and developed the GemciTest, an IVD associated with gemcitabine treatment in mPDAC. This blood signature evaluates both progression-free survival (PFS) and overall survival (OS) rates, and identifies the patients who are likely to benefit from 1st-line gemcitabine treatment. Briefly, the IVD allows to identify 37% of patients having a median overall survival of 15 months with 1-year survival rate superior to 65%. The GemciTest, a quantitative real-time PCR assay, is currently a prototype in an operational environment through a Clinician Peer Network in EU and US. In this context, Acobiom is always looking for new partnerships (public or private), the right way to open opportunities to develop the GemciTest solution for mPDAC patients (bench-to-bedside), and to assist physicians in routine patient care. Citation Format: Didier Ritter, David Piquemal, Florian Noguier, Fabien Pierrat, Roman Bruno. Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr B42.
Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B
Authors: Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Yee-Kit Tse, Lilian Yan Liang, Vicki Wing-Ki Hui, Hye Won Lee, Grace Chung-Yan Lui, Henry Lik-Yuen Chan
Journal: Journal of Hepatology (2019)
Stat3-/- Alloreactive Donor T Cells Reduce FAO but Increase Leakage of ROS in Response to PD-1 Signaling Triggered By Host-Tissue PD-L1, Leading to Prevention of Gvhd While Preserving GVL Effect
Authors: Xiaoqi Wang, Shijie Yang, Yating Wang, Xiwei Wu, Martha Salas, Qingxiao Song, Hanjun Qin, Ubaydah Nasri, Arthur D. Riggs, Paul J Martin, Xi Zhang, Defu Zeng
Journal: Blood (2019)
Abstract A53: Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis
Authors: Yasuyuki Mizutani, Hiroki Kobayashi, Atsushi Enomoto, Masahide Takahashi
Journal: Cancer Research (2019)

Abstract Cancer-associated fibroblasts (CAFs) constitute a major component of the tumor microenvironment. Recent observations in genetically engineered mouse models and clinical studies have suggested that there may exist at least two functionally different populations of CAFs, i.e., cancer-promoting CAFs (pCAFs) and cancer-restraining CAFs (rCAFs). Although various pCAF markers have been identified, the identity of rCAFs remains unknown because of the lack of rCAF-specific marker(s). In the present study, we found that Meflin, a glycosylphosphatidylinositol-anchored protein that is a marker of mesenchymal stromal/stem cells and maintains their undifferentiated state, is expressed by pancreatic stellate cells that are a source of CAFs in pancreatic ductal adenocarcinoma (PDAC). Analysis of human PDAC tissues revealed that the infiltration of Meflin-positive CAFs correlated with favorable patient outcome. Consistent herewith, Meflin deficiency led to significant tumor progression with poorly differentiated histology in a PDAC mouse model. Similarly, genetic ablation of Meflin-positive CAFs resulted in poor differentiation of tumors in a syngeneic transplantation model. Conversely, delivery of a Meflin-expressing lentivirus into the tumor stroma or overexpression of Meflin in CAFs suppressed the growth of xenograft tumors. Lineage tracing revealed that Meflin-positive cells gave rise to α-smooth muscle actin-positive CAFs that are positive or negative for Meflin, suggesting a mechanism for generating CAF heterogeneity. Mechanistically, Meflin interacts with lysyl oxidase to inhibit its collagen crosslinking activity, and Meflin deficiency resulted in straightened and wide stromal collagen fibers that represent a signature for aggressive tumors. Together, the data suggest that Meflin is a marker of rCAFs that suppress PDAC progression. Citation Format: Yasuyuki Mizutani, Hiroki Kobayashi, Atsushi Enomoto, Masahide Takahashi. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr A53.
Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children
Authors: Yizhen Li, Maoxiang Qian, Meenakshi Devidas, Wentao Yang, Stuart S. Winter, Kimberly P. Dunsmore, Colton A Smith, Ting-Nien Lin, Xuijie Zhao, Ranran Zhang, Julie M. Gastier Foster, Elizabeth A. Raetz, William L. Carroll, Karen R. Rabin, Wenjian Yang, Patrick A. Zweidler-McKay, Ching-Hon Pui, William E. Evans, Charles G. Mullighan, Stephen P. Hunger, Mary V. Relling, Mignon L. Loh, Jun J. Yang
Journal: Blood (2019)
The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
Authors: Xiaomeng Liu, Jin Xu, Bo Zhang, Jiang Liu, Chen Liang, Qingcai Meng, Jie Hua, Xianjun Yu, Si Shi
Journal: Molecular Cancer (2019)

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and is one of the most difficult-to-treat cancers. Surgical resection and adjuvant therapy have limited effects on the overall survival of PDAC patients. PDAC exhibits an immunosuppressive microenvironment, the immune response predicts survival, and activation of immune system has the potential to produce an efficacious PDAC therapy. However, chimeric antigen receptor T (CAR-T) cell immunotherapy and immune checkpoint blockade (ICB), which have produced unprecedented clinical benefits in a variety of different cancers, produce promising results in only some highly selected patients with PDAC. This lack of efficacy may be because existing immunotherapies mainly target the interactions between cancer cells and immune cells. However, PDAC is characterized by an abundant tumor stroma that includes a heterogeneous mixture of immune cells, fibroblasts, endothelial cells, neurons and some molecular events. Immune cells engage in extensive and dynamic crosstalk with stromal components in the tumor tissue in addition to tumor cells, which subsequently impacts tumor suppression or promotion to a large extent. Therefore, exploration of the interactions between the stroma and immune cells may offer new therapeutic opportunities for PDAC. In this review, we discuss how infiltrating immune cells influence PDAC development and explore the contributions of complex components to the immune landscape of tumor tissue. The roles of stromal constituents in immune modulation are emphasized. We also predict potential therapeutic strategies to target signals in the immune network in the abundant stromal microenvironment of PDAC.
Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association
Authors: Jo Ann S. Carson, Alice H. Lichtenstein, Cheryl A.M. Anderson, Lawrence J. Appel, Penny M. Kris-Etherton, Katie A. Meyer, Kristina Petersen, Tamar Polonsky, Linda Van Horn
Journal: Circulation (2019)

The elimination of specific dietary cholesterol target recommendations in recent guidelines has raised questions about its role with respect to cardiovascular disease. This advisory was developed after a review of human studies on the relationship of dietary cholesterol with blood lipids, lipoproteins, and cardiovascular disease risk to address questions about the relevance of dietary cholesterol guidance for heart health. Evidence from observational studies conducted in several countries generally does not indicate a significant association with cardiovascular disease risk. Although meta-analyses of intervention studies differ in their findings, most associate intakes of cholesterol that exceed current average levels with elevated total or low-density lipoprotein cholesterol concentrations. Dietary guidance should focus on healthy dietary patterns (eg, Mediterranean-style and DASH [Dietary Approaches to Stop Hypertension]-style diets) that are inherently relatively low in cholesterol with typical levels similar to the current US intake. These patterns emphasize fruits, vegetables, whole grains, low-fat or fat-free dairy products, lean protein sources, nuts, seeds, and liquid vegetable oils. A recommendation that gives a specific dietary cholesterol target within the context of food-based advice is challenging for clinicians and consumers to implement; hence, guidance focused on dietary patterns is more likely to improve diet quality and to promote cardiovascular health.
Results from a Phase II Trial of Pembrolizumab (P) Plus Gemcitabine (GEM) in patients (PTS) with HER2-Negative Advanced Breast Cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study
Authors: L. dela Cruz Merino, J. Cruz, J.L. Alonso, V. Quiroga Garcia, F. Moreno Anton, R. Andres, M. Santiesteban, M. Ramos Vazquez, M. Gion Cortes, J. Cortés, N. Palazon Carrion, I. Ceballos Lenza, A. Soto, M. Casas, S. Benito, S. Bezares Montes, E. Holgado
Journal: Annals of Oncology (2019)
Abstract 9913: Reduction of Insulin Like Growth Factor 1 Receptor in the Endothelium Causes an Altered Secretome Which Leads to Favourable Changes in White Adipose Tissue
Authors: Katherine Bridge, Natalie Haywood, Nele Warmke, Romana Mughal, Amy Moran, Nicole Watt, Andrew Walker, Nadira Yuldasheva, Lee Roberts, Anna Skromna, Natallia Makava, Stephen Wheatcroft, Richard Cubbon, Mark Kearney
Journal: Circulation (2019)

Introduction: In obesity the relationship between white adipose tissue expansion and neovascularisation becomes uncoupled leading to inadequate perfusion of adipose tissue. Under these circumstance...
Clinical implications of insulin-like growth factor I (IGF-I) and II (IGF-II) in stage IIIB cervical cancer.
Authors: Pooja Nandwani Patel, Rakesh Vyas, Maitrik Mehta
Journal: Journal of Clinical Oncology (2012)

e15505 Background: The IGF (Insulin like Growth Factor) family has been implicated in the pathogenesis of cervical cancer. We aim to correlate pre and post treatment levels of IGF-I and IGF-II in stage IIIB cervical cancer and identify if serum IGF-I and IGF-II can be used as a marker to predict response to chemo-radiotherapy. Methods: We recruited 80 previously untreated patients of histopathologically proven squamous cell carcinoma of stage IIIB cancer of uterine cervix from January 2011 to May 2011. The age of patients ranged from 30 to 65 years and were of ECOG performance status of less than or equal to 2. Along with the routine investigations the pretreatment serum levels of IGF-I and IGF-II were done by ELISA kits in all the patients. The serum level of IGF-I was 246.3 ± 72.5 ng/ml and IGF-II was 1585 ± 352 ng/ml. All patients were given concurrent cisplatin (30 mg/m 2 ) weekly along with radiation (50Gy/25#) with conventional portals followed by two sittings of intracavitory radiotherapy (7.5 Gy each) on mHDR. Blood samples for IGF-I and IGF-II levels were collected before the start of the therapy, 1 month after the completion of treatment and 6 months after the completion of the treatment. Results: The trend seen was that mean IGF-I levels were always in the lower range as compared to IGF-II levels in all individuals. The mean serum levels of IGF-I and IGF-II in patients who achieve complete response (45%) returned to normal whereas the mean serum levels of IGF-I and IGF-II in patients who achieved partial response (43%) was 149 ng/ml and 838 ng/ml respectively. The mean serum levels of IGF-I and IGF-II in patients who achieved no response (12%) was 331 ng/ml and 1840 ng/ml respectively. Conclusions: The serum levels of IGF-I and IGF-II may be a reliable prognostic and predictive marker in cervical cancer however further large randomized studies are required to validate the results. IGF-I and IGF-II can serve as potential markers in cervical cancer to risk stratify patients, assess treatment response and possibly act as therapeutic targets in the future.
Reply to Liang Sun and Yi Feng’s Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2019;77:55–65
Authors: Malte W. Vetterlein, Michael Rink
Journal: European Urology (2019)
Proceedings From the Global Cardio-Oncology Summit
Authors: Daniel J. Lenihan, Michael G. Fradley, Susan Dent, Christine Brezden-Masley, Joseph Carver, Roberto Kalil Filho, Tomas G. Neilan, Anne Blaes, Chiara Melloni, Joerg Herrmann, Saro Armenian, Paaladinesh Thavendiranathan, Gregory T. Armstrong, Bonnie Ky, Ludhmila Hajjar
Journal: JACC CardioOncology (2019)

The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we present the top 10 priorities for our field that were discussed at the meeting, and also detail a potential path forward to address these challenges. Defining robust predictors of cardiotoxicity, clarifying the role of cardioprotection, managing and preventing thromboembolism, improving hematopoietic stem cell transplant outcomes, personalizing cardiac interventions, building the cardio-oncology community, detecting and treating cardiovascular events associated with immunotherapy, understanding tyrosine kinase inhibitor cardiotoxicity, and enhancing survivorship care are all priorities for the field. The path forward requires a commitment to research, education, and excellence in clinical care to improve our patients' lives.
Embracing Multiple Normals — A 12-Year-Old Boy in India with a Cochlear Implant
Authors: Michele Friedner, Rema Nagarajan, Anjali Murthy, Raphael Frankfurter
Journal: New England Journal of Medicine (2019)

Interview with Dr. Michele Friedner on how the concept of normality affects health care decisions. (13:50)Download The parents of a deaf boy in India are advised to get him a cochlear implant so he can live a "normal" life. When they can't afford to maintain the device, he's left with little ability to communicate. How can the concept of "multiple normals" improve clinical practice?
Results of the NLG2105 Phase I Trial Using the IDO Pathway Inhibitor Indoximod, in Combination with Radiation and Chemotherapy, for Children with Newly Diagnosed DIPG
Authors: T.S. Johnson, D. Aguilera, A. Al-Basheer, Z. Berrong, R.C. Castellino, B.R. Eaton, N. Esiashvili, N. Foreman, I.M. Heger, E.P. Kennedy, N. Vahanian, W. Martin, R. Pacholczyk, E. Ring, R.F. Sadek, A. Smith, M. Shimoda, T.J. Macdonald, D.H. Munn
Journal: Annals of Oncology (2019)
Validation of the Amsterdam-Oxford survival prediction model in primary sclerosing cholangitis in a tertiary center setting
Authors: Jorn Goet, Annarosa Floreani, Xavier Verhelst, Nora Cazzagon, Lisa Perini, Willem J Lammers, Adriaan Van Der Meer, Annemarie C De Vries, Henk R van Buuren, Bettina E Hansen
Journal: Hepatology (2018)
Annals Graphic Medicine - Crime and Punishment
Authors: Stefan Tigges
Journal: Annals of Internal Medicine (2019)

Web Exclusives17 December 2019Annals Graphic Medicine - Crime and PunishmentFREEStefan Tigges, MDStefan Tigges, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0011 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G19-0011.Author/Illustrator Information: Stefan Tigges, MD (e-mail, [email protected]edu).This article was published at Annals.org on 10 December 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 December 2019Volume 171, Issue 12Page: W81-W85KeywordsConflicts of interestCrimeDisclosureHealth care ePublished: 10 December 2019 Issue Published: 17 December 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 18026: Is Patent Foramen Ovale (PFO) an Independent Risk Factor for Stroke in patients with Atrial Fibrillation
Authors: Vijaiganesh Nagarajan, Sachin Goel, Samir R Kapadia
Journal: Circulation (2012)

Background: Patent foreman ovale (PFO) is one of the well known risk factors for cryptogenic stroke. But no studies have evaluated whether PFO increased the risk of stroke in patients with atrial f...
Preemptive Treatment of Herpes Simplex Virus Reactivation in Critically Ill Patients?—Not Based on Current Data
Authors: David S. Y. Ong, Olaf L. Cremer, Marc J. M. Bonten
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden
Authors: Jerker Jonsson, Sharon Kühlmann-Berenzon, Ingela Berggren, Judith Bruchfeld
Journal: European Respiratory Journal (2019)

Rationale Studies investigating the risk of active tuberculosis (TB) in association with pregnancy have not been conclusive. We aimed to investigate this risk in a large retrospective register-based cohort study in Sweden. Methods Data from women of 15–49 years of age who had given birth in Sweden between 2005 and 2013 were extracted from the national childbirth register and linked to the national TB register. Cohort time was divided into three exposure periods: during pregnancy, six months (180 days) postpartum and time neither pregnant nor postpartum. We calculated incidence rates (IRs) per 100 000 person-years for each period and incidence rate ratios (IRRs) with IRs neither pregnant nor postpartum as the reference. Results The cohort included 649 342 women, of whom 553 were registered as cases of active TB, 389 when neither pregnant nor postpartum, 85 during pregnancy and 79 when postpartum. Overall IRs were 9, 12 and 17 cases per 100 000 person-years, respectively, giving IRR 1.4, 95% CI 1.1–1.7 (during pregnancy) and IRR 1.9, 95% CI 1.5–2.5 (when postpartum). Stratification by TB incidence in country of origin showed that the increased risk was concentrated amongst women from countries with a TB incidence of 100 or higher, where IRs per 100 000 person-years were 137 (when neither pregnant nor postpartum), 182 (during pregnancy) and 233 (when postpartum). Conclusion We show a significant increase in risk of active TB during both pregnancy and postpartum in women from high incidence countries and recommend TB screening in pregnant women belonging to this risk group.
127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours
Authors: M. Reck, F. Cappuzzo, D. Rodriguez-Abreu, D.C. Cho, J.K. Schwarz, M.J. Riese, A. Gupta, T. Chan, R. Saab, S. Singel, W. Lin, M. Tagliaferri, D.R. Spigel
Journal: Annals of Oncology (2019)
A Phase I Study of Percutaneous Oncolytic Rose Bengal Disodium for Metastatic Uveal Melanoma Patients with Hepatic Metastases: A Single-Center Cohort Summary
Authors: S. Patel, B.W. Carter, G. Balmes, H. Rider, J. Joseph, C. Zobniw, V. Trinh, J. Anderson, R. Sheth, R. Murthy, E.A. Wachter
Journal: Annals of Oncology (2019)
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
Authors: A. Broccoli, L. Argnani, B. Botto, P. Corradini, A. Pinto, A. Re, U. Vitolo, S. Fanti, V. Stefoni, P. L. Zinzani
Journal: Blood Cancer Journal (2019)

Abstract Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are active monotherapies in the relapsed/refractory setting and their combination (the BBV regimen) possibly enhances their activity. This single-arm multicenter phase 2 study investigated the efficacy and safety of BBV as first salvage therapy in 40 patients with relapsed/refractory HL. Thirty-eight patients were evaluable for efficacy: 30 (78.9%) had a CMR and 2 (5.3%) a partial response, leading to an overall response rate (ORR) of 84.2%. The ORR in the primary refractory subset was 75.0%, among relapsed patients it was 94.4%. Thirty-five patients could mobilize peripheral blood stem cells and 33 underwent ASCT. At a median follow-up of 23 months, the estimated 3-year overall survival and progression-free survival are 88.1% and 67.3%. During therapy, only 3 grade IV cases of neutropenia occurred and resolved within a week. No grade 4 extrahematologic toxicities were reported; skin reactions were however rather frequent (65%). These results suggest that the BBV regimen exhibits promising efficacy and a manageable toxicity in a challenging subpopulation of HL patients.